Ultragenyx Resubmits BLA for UX111 Gene Therapy for Sanfilippo Syndrome Type A to FDA

summarizeSummary

Ultragenyx Pharmaceutical has resubmitted its Biologics License Application (BLA) for UX111 gene therapy to the FDA, addressing prior regulatory concerns and including new long-term clinical data for Sanfilippo syndrome type A.

check_boxKey Events

• BLA Resubmission for UX111

  Ultragenyx Pharmaceutical Inc. has resubmitted its Biologics License Application (BLA) for UX111 (rebisufligene etisparvovec) AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA) to the U.S. Food and Drug Administration (FDA).

• Addresses Prior Complete Response Letter (CRL)

  The resubmission includes comprehensive responses to chemistry, manufacturing, and controls (CMC)-related observations outlined in a Complete Response Letter (CRL) issued in July 2025.

• Includes Longer-Term Clinical Data

  The filing contains substantial longer-term data on multiple measures of neurologic benefit and additional long-term clinical data from current patients, as requested by the FDA.

• Potential First-in-Class Therapy

  If approved, UX111 would be the first approved therapy for Sanfilippo syndrome type A, addressing a significant unmet medical need.

auto_awesomeAnalysis

Ultragenyx Pharmaceutical's resubmission of the Biologics License Application (BLA) for UX111 is a critical step forward for a potential first-in-class gene therapy. The company has addressed the Chemistry, Manufacturing, and Controls (CMC) observations from the July 2025 Complete Response Letter (CRL) and included additional long-term clinical data. This move signals progress in overcoming prior regulatory hurdles and brings the company closer to potentially launching a significant treatment for Sanfilippo syndrome type A, a condition with no approved therapies. Investors should monitor the FDA's review process and the anticipated PDUFA action date in Q3 2026, as approval would unlock a new revenue stream and validate the company's gene therapy platform.